A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

NCT05141747 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Gastric Cancer
Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions

DRUG: MRG002

Sponsor

Shanghai Miracogen Inc.